Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
2.590
0.00 (0.00%)
Nov 5, 2024, 11:11 AM EST - Market open

Company Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.

The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition.

The company is headquartered in New York, New York.

Protara Therapeutics, Inc.
Protara Therapeutics logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 27
CEO Jesse Shefferman

Contact Details

Address:
345 Park Avenue South, 3rd Floor
New York, New York 10010
United States
Phone 646 844 0337
Website protaratx.com

Stock Details

Ticker Symbol TARA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001359931
CUSIP Number 74365U107
ISIN Number US74365U1079
Employer ID 20-4580525
SIC Code 2836

Key Executives

Name Position
Jesse Shefferman Co-founder, Chief Executive Officer, President and Director
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Co-Founder, Senior Vice President and Chief Scientific Operations Officer
Patrick Fabbio M.B.A. Chief Financial Officer
Hannah Fry Vice President, Principal Accounting Officer and Controller
Justine O'Malley Senior Vice President of Investor Relations and Corporate Affairs
Mary J. Grendell General Counsel and Corporate Secretary

Latest SEC Filings

Date Type Title
Aug 6, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report
Jun 10, 2024 8-K Current Report
May 9, 2024 EFFECT Notice of Effectiveness
May 9, 2024 424B3 Prospectus
May 7, 2024 UPLOAD Filing
May 2, 2024 S-3 Registration statement under Securities Act of 1933
May 2, 2024 10-Q Quarterly Report
May 2, 2024 8-K Current Report